NICE Rejects Akcea’s High-Cost Waylivra
Data Doubts Also An Issue
Initial knock-back from NICE means Akcea will need to improve commercial offer.
You may also be interested in...
NICE has given the green light to Akcea Therapeutics’ ultra-rare disease treatment Tegsedi (inotersen) after the company offered a better “commercial arrangement.”
Veklury is now the first US FDA-approved treatment for COVID-19, but its limited benefits means its lifespan as a blockbuster could be short.
Many clinicians doubt that aducanumab can really help slow the decline in Alzheimer’s patients – but US FDA could offer it the benefit of the doubt.